NYSE - Delayed Quote • USD
Novartis AG (NVS)
At close: April 25 at 4:00 PM EDT
After hours: April 25 at 7:27 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 17 | 17 |
| Avg. Estimate | 1.84 | 1.89 | 7.18 | 7.94 |
| Low Estimate | 1.78 | 1.86 | 6.7 | 7.38 |
| High Estimate | 1.9 | 1.93 | 7.83 | 8.6 |
| Year Ago EPS | 1.83 | 1.83 | 6.9 | 7.18 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 2 | 16 | 16 |
| Avg. Estimate | 12.15B | 12.27B | 48.73B | 51.01B |
| Low Estimate | 11.99B | 12.23B | 47.04B | 49.33B |
| High Estimate | 12.38B | 12.31B | 50.41B | 53.88B |
| Year Ago Sales | 13.62B | 11.78B | 45.44B | 48.73B |
| Sales Growth (year/est) | -10.80% | 4.10% | 7.20% | 4.70% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | 1.68 | 1.7 | 1.68 | 1.69 |
| EPS Actual | 1.83 | 1.83 | 1.53 | 1.8 |
| Difference | 0.15 | 0.13 | -0.15 | 0.11 |
| Surprise % | 8.90% | 7.60% | -8.90% | 6.50% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 1.84 | 1.89 | 7.18 | 7.94 |
| 7 Days Ago | 1.81 | 1.86 | 7.13 | 7.86 |
| 30 Days Ago | 1.81 | 1.85 | 7.14 | 7.88 |
| 60 Days Ago | 1.86 | 1.88 | 7.17 | 7.9 |
| 90 Days Ago | 1.88 | 1.91 | 7.3 | 8.05 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 2 | 8 | 6 |
| Up Last 30 Days | 2 | 3 | 9 | 9 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | 1 | 2 |
Growth Estimates
| CURRENCY IN USD | NVS | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 0.50% | -- | -- | 2.60% |
| Next Qtr. | 3.30% | -- | -- | 13.40% |
| Current Year | 4.10% | -- | -- | 5.20% |
| Next Year | 10.60% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 9.35% | -- | -- | 11.11% |
| Past 5 Years (per annum) | 5.78% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | BMO Capital: Market Perform to Market Perform | 4/24/2024 |
| Initiated | BMO Capital: Market Perform | 2/23/2024 |
| Initiated | Morgan Stanley: Equal-Weight | 1/23/2024 |
| Upgrade | Morgan Stanley: Underweight to Equal-Weight | 9/25/2023 |
| Downgrade | Wolfe Research: Outperform to Peer Perform | 5/9/2022 |
| Downgrade | Exane BNP Paribas: Outperform to Neutral | 12/6/2021 |
Related Tickers
SNY Sanofi
49.36
+5.90%
AZN AstraZeneca PLC
75.03
+5.38%
BMY Bristol-Myers Squibb Company
44.70
-8.51%
GSK GSK plc
40.91
+0.12%
RHHBY Roche Holding AG
30.02
-1.70%
MRK Merck & Co., Inc.
130.72
+2.93%
BIIB Biogen Inc.
202.46
+0.23%
AMGN Amgen Inc.
269.38
-1.33%
ABBV AbbVie Inc.
167.29
-0.30%
GILD Gilead Sciences, Inc.
65.27
-2.70%